医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ReproCELL: Joint Press Announcement with Institute for Frontier Medical Sciences, Kyoto University:New High-performance Cryopreservation Solution for Human ES/iPS Cells Used in Regenerative MedicineNotice of the Commencement of Sal

2015年08月26日 PM09:00
このエントリーをはてなブックマークに追加


 

YOKOHAMA, Japan

We hereby wish to inform you that, on August 20th 2015, in conjunction with the Institute for Frontier Medical Sciences, Kyoto University, ReproCELL announced to the press the release of “ReproCryo DMSO free”, our high-performance cryopreservation solution for human ES/iPS cells required in regenerative medicine, and start to commence sales of the product.

In regenerative medicine, the long-term freeze-preservation and banking of large quantities of human ES/iPS cells is an essential process. ReproCELL has succeeded in developing “ReproCryo DMSO free”, a new cryopreservation solution that is optimal for use in regenerative medicine. This cryopreservation solution consists solely of components scientifically proven to be highly safe, thus delivering a high degree of safety within the field of regenerative medicine. “ReproCryo DMSO free” also allows for the simultaneous freezing of a large quantity of cells, thus making the product suitable for automated processing. This technology represents a major contribution to the realization of regenerative medicine, which utilizes human ES/iPS cells.

The product was jointly developed with the Institute for Frontier Medical Sciences, Kyoto University in a development project for Japan Agency for Medical Research and Development (AMED), the national research and development corporation which was inaugurated in April this year.

Taking advantage of our strengths in global-scale advanced research networks and the superior technology of the ES/iPS cells we have cultivated thus far, our company group is advancing initiatives in the field of regenerative medicine. “ReproCryo DMSO free” holds an extremely important position as a product working for the promotion of regenerative medicine and is expected to make a significant contribution to the expansion of our group’s business.

For more information, visit: https://www.reprocell.com/en/

View source version on businesswire.com: http://www.businesswire.com/news/home/20150826005494/en/

CONTACT

ReproCELL, Inc. (JASDAQ Company code: 4978)
Chikafumi Yokoyama,
+81-45-475-3887
PhD
info_en@reprocell.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作